Related Experiment Videos
What is the relevance of the HOPE study in general practice?
J Kennedy1, C E Mogensen, S G Ball
1Medical Department M (Diabetes and Endocrinology), Aarhus Kommunehospital, Denmark.
Insights
The Heart Outcomes Prevention Evaluation (HOPE) study shows that ramipril, an ACE inhibitor, effectively prevents cardiovascular events in high-risk patients, including those with diabetes. Long-term use is safe and recommended for eligible individuals.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are underprescribed in primary care.
- High-risk cardiovascular patients and those with diabetes require effective preventive strategies.
Purpose of the Study:
- To evaluate the efficacy of ramipril as a preventive agent in high-risk cardiovascular patients.
- To assess the benefits of ramipril in diabetic patients.
Main Methods:
- The study involved patients at high risk of cardiovascular events with normal left ventricular function.
- Ramipril was administered as a long-term therapeutic addition.
Main Results:
- Ramipril significantly reduced cardiovascular events in high-risk patients.
- Ramipril demonstrated significant benefits for diabetic patients.
- Ramipril was well-tolerated at high doses and over extended treatment periods.
Conclusions:
- Ramipril is a valuable preventive therapy for high-risk cardiovascular patients and diabetics.
- Long-term ramipril therapy should be considered for eligible patients.
- Monitoring of kidney function and serum potassium is recommended during ramipril treatment.
Abstract:
The unique findings from the HOPE (Heart Outcomes Prevention Evaluation) study strongly support extending the use of the angiotensin-converting enzyme (ACE) inhibitor ramipril as a preventive agent for patients at high risk of cardiovascular events with normal left ventricular function. In addition, ramipril provides significant benefit in diabetic patients. These findings will impact on how ramipril is used in primary care, where ACE inhibitors are currently underprescribed. Patients reflecting the inclusion criteria of the HOPE study should be considered as suitable candidates for long-term ramipril therapy as an addition to their existing drug regimen. Screening should include control of kidney function (by serum creatinine), particularly within the first two weeks of treatment, in addition to regular monitoring of serum potassium. However, the HOPE study shows that ramipril is well tolerated at high doses and over a long treatment period. The effectiveness of therapy should also be regularly reviewed and dose adjustments made where necessary. If concern remains, referral to a specialist--a cardiologist or a diabetologist--may ultimately be necessary.